Edition:
United Kingdom

Abbott Q3 adjusted EPS $0.66 from continuing operations


Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Abbott Laboratories ::Abbott reports third-quarter 2017 results.Sees FY 2017 gaap earnings per share $0.97 to $0.99 from continuing operations.Q3 adjusted earnings per share $0.66 from continuing operations.Q3 gaap earnings per share $0.32 from continuing operations.Q3 earnings per share view $0.65 -- Thomson Reuters I/B/E/S.Sees Q4 adjusted earnings per share $0.72 to $0.74 from continuing operations excluding items.Sees FY 2017 adjusted earnings per share $2.48 to $2.50 from continuing operations.Sees Q4 2017 gaap earnings per share $0.28 to $0.30 from continuing operations.Q3 sales $6.8 billion versus I/B/E/S view $6.72 billion.Abbott Laboratories - ‍narrowed its full-year 2017 eps guidance range​.Abbott Laboratories qtrly total pediatric sales $‍975​ million, up 0.8 percent on a reported basis.Abbott Laboratories qtrly total nutrition sales $1,768 million, up 0.8 percent on a reported basis‍​.Abbott Laboratories - qtrly total vascular sales $‍724​ million, up 17.1 percent on reported basis.Abbott Laboratories - qtrly total diagnostics sales $1,279 million, up 5.4 percent on a reported basis ‍​.Abbott Laboratories - ‍on Oct. 3, 2017, Abbott completed acquisition of Alere​.FY 2017 earnings per share view $2.50 -- Thomson Reuters I/B/E/S.Q4 earnings per share view $0.74 -- Thomson Reuters I/B/E/S.Abbott Laboratories - ‍expects to initiate launch of its alinity systems in U.S. In 2018​.